SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZTC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Barbara Bullard who wrote (493)1/7/1998 10:29:00 AM
From: Giuseppe Scalamogna  Read Replies (1) of 752
 
Barbara,

I will give a technical update after today's close.

As far as other candidates for a possible takeover of GZTC is really sketchy to pick out. Obviously with the viability of a transgenic program becoming more tangible it would certainly be a wondrous addition to any of the large pharmaceutical companies' programs, the likes of Merck, Pharmacia/Upjohn, and Warner Lambert to name a few. Bristol Meyers Squibb in my mind would be the leading candidate on this list via their several collaborations with GZTC to transgenically produce biologics of BMY's interest. They in fact have seemed to have taken the most interest in GZTC's technology through their investments in GZTC's business. If Bristol Meyers were in fact the lead candidate, the deal could be very lucrative for Genzyme General as they hold that 44% stake which in accounting terms in a influential yet non-controlling investment.

GS
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News